Uremic pruritus. Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Conditions
Interventions
Intervention 1: placebo. Intervention 2: oral nicotinamide 500 mg two times a day.
Placebo
Treatment - Drugs
placebo
oral nicotinamide 500 mg two times a day
Sponsors
Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: known cases of end-stage renal disease patients treated with hemodialysis; ages between 18 and 60 years; At least 6 weeks history of pruritus; no systemic or topical treatment for the pruritus. Exclusion criteria: a known hypersensitivity to nicotinamide; suffering from other known skin diseases, liver disorders, metabolic disorders, any other condition except for CRD causing pruritus; any serious systemic disease; Usage of antihistamines or other anti-pruritus drugs in the last three months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attenuation of uremic pruritus. Timepoint: Four weeks. Method of measurement: By using a traditional Visual Analogue Scale (VAS) and a modified questionnaire method (pruritus score). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Khazanee
Jundishapur University of Medical Sciences
Outcome results
None listed